Yesterday, May 25, 2016, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $88.32 to $137,937,966.40.

Highlighted Stocks Traded by Insiders:

Depomed (DEPO) - FREE Research Report

Vargas Thadd M, who is Senior VP, BD at Depomed, sold 15,000 shares at $20.00 on May 25, 2016. Following this transaction, the Senior VP, BD owned 109,297 shares meaning that the stake was reduced by 12.07% with the 15,000-share transaction.

The shares most recently traded at $19.94, down $0.06, or 0.3% since the insider transaction. Historical insider transactions for Depomed go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 43,000
  • 24-Week # shares sold: 53,000

The average volume for Depomed has been 2.1 million shares per day over the past 30 days. Depomed has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 10.09% year-to-date as of the close of trading on Wednesday.

Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. Currently, there are 9 analysts who rate Depomed a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DEPO - FREE

TheStreet Quant Ratings

rates Depomed as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full

Depomed Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ARIAD Pharmaceuticals (ARIA) - FREE Research Report

Clackson Timothy P, who is President, R&D, CSO at ARIAD Pharmaceuticals, sold 17,762 shares at $8.08 on May 25, 2016. Following this transaction, the President, R&D, CSO owned 288,741 shares meaning that the stake was reduced by 5.8% with the 17,762-share transaction.

The shares most recently traded at $8.07, down $0.01, or 0.06% since the insider transaction. Historical insider transactions for ARIAD Pharmaceuticals go as follows:

  • 4-Week # shares bought: 26,990
  • 4-Week # shares sold: 21,409
  • 12-Week # shares bought: 26,990
  • 12-Week # shares sold: 45,243
  • 24-Week # shares bought: 88,089
  • 24-Week # shares sold: 60,665

The average volume for ARIAD Pharmaceuticals has been 4.2 million shares per day over the past 30 days. ARIAD Pharmaceuticals has a market cap of $1.5 billion and is part of the health care sector and drugs industry. Shares are up 30.4% year-to-date as of the close of trading on Wednesday.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. Currently, there are 3 analysts who rate ARIAD Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARIA - FREE

TheStreet Quant Ratings

rates ARIAD Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and deteriorating net income. Get the full

ARIAD Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Rogers (ROG) - FREE Research Report

Jensen Carol R, who is Director at Rogers, sold 1,400 shares at $63.01 on May 25, 2016. Following this transaction, the Director owned 14,988 shares meaning that the stake was reduced by 8.54% with the 1,400-share transaction.

Zhang Helen, who is VP, PES, President Rogers Asia at Rogers, sold 2,392 shares at $62.08 on May 25, 2016. Following this transaction, the VP, PES, President Rogers Asia owned 9,383 shares meaning that the stake was reduced by 20.31% with the 2,392-share transaction.

The shares most recently traded at $64.78, up $2.70, or 4.17% since the insider transaction. Historical insider transactions for Rogers go as follows:

  • 4-Week # shares bought: 1,650
  • 4-Week # shares sold: 15,700
  • 12-Week # shares bought: 1,650
  • 12-Week # shares sold: 17,400
  • 24-Week # shares bought: 1,650
  • 24-Week # shares sold: 17,400

The average volume for Rogers has been 110,100 shares per day over the past 30 days. Rogers has a market cap of $1.2 billion and is part of the technology sector and electronics industry. Shares are up 26.64% year-to-date as of the close of trading on Wednesday.

Rogers Corporation designs, develops, manufactures, and sells engineered materials and components worldwide. The company has a P/E ratio of 25.4. Currently, there is 1 analyst who rates Rogers a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ROG - FREE

TheStreet Quant Ratings

rates Rogers as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Rogers Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.